Alzheimer’s, dementia and the endocannabinoid system

Alzheimer’s dementia is the most common neurodegenerative disease – more than 1.8 million people are affected in Germany. The endocannabinoid system (ECS) plays a previously underestimated role in the pathophysiology: CB1 receptors in the hippocampus and entorhinal cortex – both regions that degenerate early in Alzheimer’s – regulate memory consolidation and synaptic plasticity. CB2 receptors on microglial cells control neuroinflammation, which drives amyloid-β plaques.

In Alzheimer’s patients, reduced anandamide levels and downregulated CB1 receptors are found in the entorhinal cortex – an ECS deficit that correlates with cognitive deterioration.

Clinical and preclinical study overview

Neuroprotection: How cannabis could slow down Alzheimer’s disease

Amyloid-β reduction: CBD inhibits the aggregation of amyloid-β proteins into toxic oligomers (the precursor of plaques). CBD activates PPARγ – a nuclear transcription factor that shifts amyloid precursor protein processing towards non-amyloidogenic pathways.

Tau pathology: THC inhibits acetylcholinesterase in vitro (similar to Alzheimer’s drugs such as donepezil) and in animal models shows reduction of tau aggregation via GSK-3β inhibition – the kinase enzyme that drives tau hyperphosphorylation.

Neuroinflammation: Microglia are the main initiators of neuroinflammation in Alzheimer’s disease. CB2 on microglia controls their polarization: CB2 activation by CBD and THC shifts microglia from M1 (proinflammatory, toxic) to M2 (anti-inflammatory, phagocytic). M2 microglia clear amyloid plaques from the brain more efficiently.

Neuroprotective signaling pathways: CBD activates BDNF (Brain-Derived Neurotrophic Factor) and VEGF – growth factors that promote neurogenesis in the hippocampus and maintain synaptic connections.

Symptom control: What cannabis can actually help

In addition to neuroprotective effects, it is above all the accompanying symptoms of dementia that can be better controlled with medicinal cannabis:

Agitation and aggression: the most common problem in dementia care. THC (dronabinol) has been shown to dampen amygdala hyperactivity and reduce NPI score. Alternative to antipsychotics (haloperidol, risperidone), which increase the risk of stroke.

Sleep disorders: CB1 activation prolongs deep sleep phases, suppresses REM sleep (reduces nightmares). Dronabinol studies show consistent sleep improvement in dementia patients.

Pain: Dementia patients are often unable to articulate pain, which promotes underuse. Cannabis analgesia also works in cognitively impaired patients and is spinal cord-mediated – not dependent on cognitive processing.

Appetite/weight: Weight loss is an independent predictor of mortality in Alzheimer’s disease. THC stimulates appetite via hypothalamus-CB1, promotes weight gain.

Dronabinol vs CBD: Which one for dementia?

Dronabinol (synthetic THC): Better for behavioral and sleep problems. Approved for other indications (nausea, cachexia), off-label for dementia. Advantage: dosable, no smoking, SHI reimbursement possible.

CBD: Better for neuroprotective and anti-inflammatory effects. Available in Germany as a prescription drug. Dosage in studies: 150-600 mg/day for neuroprotective effects – significantly higher than usual CBD oil concentrations.

Combination: Theoretically synergistic – THC for behavior/sleep, CBD for neuroprotection. Clinical data on the combination in Alzheimer’s is still limited.

SHI reimbursement for dementia

Medical cannabis for dementia can be reimbursed for:
– Agitation/aggression when antipsychotics are contraindicated or ineffective
– Severe sleep disorders
– Pain with communication impairment

Application via neurologist or geriatric psychiatrist with documentation of previous therapies and NPI score history.

FAQ: Cannabis for Alzheimer’s and dementia

Summary

The ECS is directly involved in Alzheimer’s pathophysiology: CB1 regulates memory systems, CB2 controls microglial activity. CBD reduces amyloid plaques and neuroinflammation in animal models via PPARγ and CB2. Similar to Parkinson’s disease, it is mainly accompanying symptoms – agitation, sleep, pain – for which medical cannabis is already being used clinically today. Dronabinol is the preferred form in dementia care. SHI reimbursement possible in cases of treatment resistance.